Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ATAI's main value driver is BPL-003. This candidate showed rapid and durable TRD benefits in its Phase 2b trials. BPL-003's 8 mg dose seemed to be ideal, which is why ATAI is going ahead with a Phase 3 with this dosing by Q2 2026. ATAI's broader pipeline includes VLS-01 DMT buccal film, EMP-01 R-MDMA for SAD, and other early-stage non-hallucinogenic 5-HT2A candidates.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has priced its registered underwritten offering of 23,725,000 company common shares at $5.48 per share, with expectations of raising about $130 million.  The clinical-stage biopharmaceutical company said it intends to use the net proceeds of the offering, together with existing cash, cash equivalents and short-term investments, to advance the clinical development of its product candidates and programs, as well as for working capital and general corporate purposes.

Atai Life Sciences (ATAI -7.63%), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer group.

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adult patients with treatment-resistant depression (TRD). The FDA's Breakthrough Therapy designation is intended to accelerate the development of drugs for serious or life-threatening conditions where preliminary clinical evidence indicates the therapy may offer substantial improvement over existing treatments.

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Glenn Short spoke with Proactive about the company's recent NIH grant and its innovative discovery program targeting opioid use disorder (OUD).  Short explained that the NIH grant review process is “highly competitive,” with independent experts assessing the novelty and potential impact of atai's work.

Atai Life Sciences N.V. has surged >275% YTD, driven by promising psychedelic drug candidates targeting treatment-resistant depression and other mental health disorders. ATAI's lead asset, BPL-003, shows strong, durable efficacy in early trials, potentially surpassing Spravato, but regulatory and scheduling hurdles remain significant risks. Despite a tight cash position and upcoming milestones, ATAI's valuation may be fair or slightly overvalued, with major catalysts like Phase 2b/3 data and FDA discussions ahead.